+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Gocovri"

Cerebral Palsy Treatment Global Market Report 2024 - Product Thumbnail Image

Cerebral Palsy Treatment Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
Dyskinesia - Pipeline Insight, 2024 - Product Thumbnail Image

Dyskinesia - Pipeline Insight, 2024

  • Clinical Trials
  • February 2024
  • 80 Pages
  • Global
From
From
Global Parkinson's Disease Drugs Market 2018-2024 - Product Thumbnail Image

Global Parkinson's Disease Drugs Market 2018-2024

  • Report
  • March 2019
  • 110 Pages
  • Global
From
Disease Analysis: Parkinson's Disease - Product Thumbnail Image

Disease Analysis: Parkinson's Disease

  • Report
  • March 2021
  • 75 Pages
  • Global
Gocovri - Product Thumbnail Image

Gocovri

  • Report
  • June 2018
  • 15 Pages
  • Global
From
  • 7 Results (Page 1 of 1)
Loading Indicator

Gocovri is a central nervous system (CNS) drug used to treat dyskinesia in patients with Parkinson's disease. Dyskinesia is a condition characterized by involuntary movements of the body, which can be disabling and interfere with daily activities. Gocovri is an extended-release form of amantadine, a drug that has been used to treat Parkinson's disease for decades. Gocovri is the first and only FDA-approved treatment for dyskinesia in Parkinson's disease. Gocovri is part of a larger market of CNS drugs, which includes treatments for a variety of neurological conditions, such as Alzheimer's disease, multiple sclerosis, and epilepsy. These drugs are used to manage symptoms, slow the progression of the disease, and improve quality of life. Some companies in the CNS drug market include AbbVie, Biogen, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Teva Pharmaceuticals. Show Less Read more